Brightsurf Science News & Current Events

May 19, 2002
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer
An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B.

Childhood cancer survivors: Good health for some, long-term complications for others
Results from the Childhood Cancer Survivor Study (CCSS) have found that the majority of survivors of childhood cancer report overall general good health, but the therapies that were used to cure some survivors may put them at increased risk for long-term complications.

Understanding cancer patients' needs, concerns, is key to improving clinical trial participation
Advances in cancer treatment depend on carefully controlled trials of new therapies, yet only two to four percent of cancer patients nationwide take part in these pivotal studies.

New treatment reduces liver tumors and improves quality of life for cancer patients
A new treatment option for inoperable primary liver cancer called TheraSphere® appears to be safe and effective for liver cancer patients, according to results presented by a University of Pittsburgh researcher at the 38th Annual Meeting of the American Society for Clinical Oncology (ASCO).

Molecularly targeted drug slows tumor growth in patients
Researchers from the National Cancer Institute (NCI) reported today that the molecularly targeted drug bevacizumab slowed tumor growth in patients with metastatic renal cell carcinoma, the most common form of kidney cancer in adults.

Gemcitabine demonstrates promise as a low toxic chemotherapeutic agent for bladder cancer
Patients with bladder cancer could benefit from treatment with gemcitabine (Gemzar®), a chemotherapeutic agent that has been used successfully to treat pancreatic cancer and non-small cell lung cancer, according to phase I trial results reported at the 38th Annual Meeting of the American Society for Clinical Oncology (ASCO) by Merrill J.

Genetic fingerprinting improves diagnosis and treatment of sarcoma
Decades of research into the cell's molecular mechanics have produced a promising arsenal of drugs that selectively attack cancer cells and leave the surrounding normal tissue relatively untouched.

Cell Genesys reports long term survival data in Phase II trial of GVAX prostate cancer vaccine
Phase II multicenter clinical trial of GVAX® prostate cancer vaccine demonstrates a dose-dependent trend toward prolonged survival in patients with hormone refractory prostate cancer metastatic to bone. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to